News
Article
Author(s):
Upadacitinib’s targeted inhibition of JAK1 offers a novel strategy for managing bullous pemphigoid and, in rare, treatment-resistant cases, may induce sustained remission following immune modulation.
Bullous pemphigoid (BP) is a chronic autoimmune blistering disease characterized by tense bullae, severe pruritus, and circulating autoantibodies against hemidesmosomal proteins. Standard first-line therapy includes systemic corticosteroids, often supplemented by doxycycline or steroid-sparing immunosuppressants such as azathioprine or mycophenolate mofetil.1,2 Despite these options, a significant proportion of patients experience relapses or fail to achieve adequate control, prompting the need for alternative therapies.
Upadacitinib (Rinvoq; AbbVie) is an oral JAK1-selective inhibitor currently approved for conditions such as rheumatoid arthritis and atopic dermatitis. Although not FDA approved for BP, emerging evidence suggests a role for JAK/STAT signaling in BP pathogenesis.3-5 Elevated levels of Th2 cytokines—including IL-4 and IL-13—activate this pathway, supporting a rationale for JAK1 inhibition in refractory cases.6,7 This case report illustrates successful remission of BP using upadacitinib after failure of conventional and biologic therapies.8
A 72-year-old man presented with a blistering eruption involving the left hand and forearm. A lesional skin biopsy revealed subepidermal vesicular dermatitis with eosinophils and neutrophils. Although the histology was suggestive of BP, the diagnosis was confirmed via indirect immunofluorescence, which showed elevated BP180 immunoglobulin G antibodies (14.1 U/mL, reference < 9).
Initial treatment included systemic prednisone taper, doxycycline, and niacinamide. However, disease control remained elusive. The patient subsequently underwent 6-month trials of dupilumab and omalizumab—both without success. Although prednisone offered partial control, flares recurred with tapering. Given his refractory disease course, upadacitinib was initiated at 15 mg every other day.
Within 2 months, the patient experienced marked clinical improvement, with resolution of existing lesions and no new blister formation. After 6 months, upadacitinib was reduced to 7.5 mg every other day and eventually discontinued entirely after 1 year. The patient has remained in remission without any therapy for an additional 18 months.
This case highlights an emerging therapeutic strategy in dermatology: the off-label use of JAK inhibitors for autoimmune blistering diseases. Several important clinical considerations include the following:
This case report adds to the growing body of literature on JAK inhibitors in dermatology by documenting a rare instance of sustained remission of BP following upadacitinib therapy. Upadacitinib’s targeted inhibition of JAK1 offers a new therapeutic avenue for BP by blocking Th2-associated cytokines involved in disease pathogenesis and, in rare cases, may induce durable remission in otherwise refractory presentations. For patients with treatment-resistant disease, upadacitinib may represent a viable off-label option with durable benefits. Clinicians should remain aware of this emerging therapeutic avenue as the landscape of immune-modulating treatments continues to evolve.
Jennifer Fisher, MMSc, PA-C, is a board-certified dermatology physician assistant and medical writer in Connecticut.
References
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.